With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
News & Analysis: Exelixis
These revenue-producing, possible acquisition candidates may be the right medicine to heal your portfolio.
The biotech needed help from some friends to get there.
EXEL earnings call for the period ending June 30, 2019.
These three businesses are poised to profit from the war on cancer.
This biotech might be a one-trick pony for now. But it's got a great horse to ride.
These three businesses are a great way for investors to support the war on cancer.
Sometimes, you hear the bad news from a friend of a friend.
These stocks are leading the way in their respective areas in battling cancer.
You have to look hard to see value in today's pricey market, but here are three inexpensive stocks that should be on your radar today.